- Home
- NRP vs ETNB Comparison
NRP vs ETNB Comparison
Compare NRP & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRP
- ETNB
- Stock Information
- Founded
- NRP 2002
- ETNB 2018
- Country
- NRP United States
- ETNB United States
- Employees
- NRP N/A
- ETNB N/A
- Industry
- NRP Coal Mining
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- NRP Energy
- ETNB Health Care
- Exchange
- NRP Nasdaq
- ETNB Nasdaq
- Market Cap
- NRP 1.3B
- ETNB 1.0B
- IPO Year
- NRP N/A
- ETNB 2019
- Fundamental
- Price
- NRP $99.25
- ETNB $7.79
- Analyst Decision
- NRP
- ETNB Strong Buy
- Analyst Count
- NRP 0
- ETNB 9
- Target Price
- NRP N/A
- ETNB $27.25
- AVG Volume (30 Days)
- NRP 18.4K
- ETNB 1.5M
- Earning Date
- NRP 05-06-2025
- ETNB 05-01-2025
- Dividend Yield
- NRP 4.31%
- ETNB N/A
- EPS Growth
- NRP N/A
- ETNB N/A
- EPS
- NRP 10.41
- ETNB N/A
- Revenue
- NRP $229,151,000.00
- ETNB N/A
- Revenue This Year
- NRP N/A
- ETNB N/A
- Revenue Next Year
- NRP N/A
- ETNB N/A
- P/E Ratio
- NRP $9.47
- ETNB N/A
- Revenue Growth
- NRP N/A
- ETNB N/A
- 52 Week Low
- NRP $81.74
- ETNB $4.16
- 52 Week High
- NRP $113.04
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- NRP 46.94
- ETNB 54.56
- Support Level
- NRP $95.79
- ETNB $6.55
- Resistance Level
- NRP $104.99
- ETNB $8.92
- Average True Range (ATR)
- NRP 3.67
- ETNB 0.57
- MACD
- NRP -0.18
- ETNB 0.17
- Stochastic Oscillator
- NRP 34.67
- ETNB 63.69
About NRP Natural Resource Partners LP Limited Partnership
Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. The business activity of the group functions through the United States.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).